Pere Santamaria is a professor in the Department of Microbiology, Immunology and Infectious Diseases and director of the Julia McFarlane Diabetes Research Centre in the Faculty of Medicine at the University of Calgary (AB, Canada). He is also a group leader at the Institut d‘Investigacions Biomediques August Pi i Sunyer in Barcelona, Spain, and Scientific Founder of Parvus Therapeutics, Inc. He earned an MD and PhD degree from the University of Barcelona (Barcelona, Spain) in 1983 and 1987, respectively, and completed his medical speciality training in clinical immunology in 1987, also in Barcelona. From 1988 to 1992, he pursued postdoctoral research training in the Department of Medicine and Institute of Human Genetics at the University of Minnesota (MN, USA). He joined the Faculty of Medicine at the University of Calgary in 1992 as an assistant professor. In 2009, he was the founder of Parvus Therapeutics Inc., a biopharmaceutical company that specializes in the development of nanovaccines for the treatment of autoimmune diseases. Santamaria has been the recipient of several honors and awards, including the Alberta Heritage Foundation for Medical Research Senior Scholar, Scientist and Senior Scientist awards, the Canadian Diabetes Association Young Investigator award and the Juvenile Diabetes Research Foundation Scholar award, among others. Over the years, Santamaria has served on numerous national and international grant review committees, serves on the editorial boards of several scientific journals, and is a regular reviewer for many others. Santamaria’s research focuses on the pathogenesis, immunogenetics and treatment of autoimmune Type 1 diabetes. He currently holds major research grants from several national and international granting agencies, holds several patents and patent applications, speaks regularly at national and international scientific meetings, research institutions and universities and has written more than 150 publications.